From WikiProjectMed
Jump to navigation Jump to search
Trade namesSotyktu
Other namesBMS-986165
  • 6-(Cyclopropanecarbonylamido)-4-[2-methoxy-3-(1-methyl-1,2,4-triazol-3-yl)anilino]-N- (trideuteriomethyl)pyridazine-3-carboxamide
Clinical data
Drug classTYK2 inhibitor[1]
Main usesPlaque psoriasis[1]
Side effectsUpper respiratory infections, herpes simplex, folliculitis, acne[1]
Routes of
By mouth
Typical dose6 mg OD[1]
External links
Legal status
Protein binding82–90%
MetabolismLiver (primarily CYP1A2)
MetabolitesBMT-153261 (active)
Elimination half-life10 hours
ExcretionFeces, urine
Chemical and physical data
Molar mass422.449 g·mol−1
3D model (JSmol)
  • [2H]C([2H])([2H])NC(=O)C1=NN=C(C=C1NC2=CC=CC(=C2OC)C3=NN(C=N3)C)NC(=O)C4CC4
  • InChI=1S/C20H22N8O3/c1-21-20(30)16-14(9-15(25-26-16)24-19(29)11-7-8-11)23-13-6-4-5-12(17(13)31-3)18-22-10-28(2)27-18/h4-6,9-11H,7-8H2,1-3H3,(H,21,30)(H2,23,24,25,29)/i1D3

Deucravacitinib, sold under the brand name Sotyktu, is a medication used to treat moderate to severe plaque psoriasis.[1] It should not be used with other strong immunosuppressants.[1] It is take by mouth.[1]

Common side effects include upper respiratory infections, herpes simplex, folliculitis, and acne.[1] Other side effects may include allergic reactions, infection, cancer, and muscle breakdown.[1] Use in pregnancy is of unclear safety.[1] Use is not recommended in those with significant liver problems.[1] It is a TYK2 inhibitor.[1]

Deucravacitinib was approved for medical use in the United States in 2022.[1] As of 2022 it is not approved in Europe or the United Kingdom.[2] In the United States it costs about 6,200 USD per month.[2]

Medical use


It is take at a dose of 6 mg once per day.[1]

Mechanism of action

Deucravacitinib inhibits TYK2 activation by interacting with JH2 domain, while first-generation jakinibs inhibit enzymatic activity by binding to ATP-binding domain[3]

It acts as a highly selective allosteric inhibitor of non-receptor tyrosine-protein kinase 2 (TYK2).[4]

Molecule design

The chemical structure of deucravacitinib contains a methyl amide in which all three hydrogen atoms are replaced by deuterium.[5]


It was developed by Bristol Myers Squibb.[6]


  1. 1.00 1.01 1.02 1.03 1.04 1.05 1.06 1.07 1.08 1.09 1.10 1.11 1.12 1.13 1.14 "Sotyktu- deucravacitinib tablet, film coated". DailyMed. 9 September 2022. Archived from the original on 28 September 2022. Retrieved 27 September 2022.
  2. 2.0 2.1 "Deucravacitinib". SPS - Specialist Pharmacy Service. 1 November 2018. Archived from the original on 29 June 2022. Retrieved 13 December 2022.
  3. Alexander, Madison; Luo, Yiming; Raimondi, Giorgio; O'Shea, John J.; Gadina, Massimo (30 December 2021). "Jakinibs of All Trades: Inhibiting Cytokine Signaling in Immune-Mediated Pathologies". Pharmaceuticals (Basel, Switzerland). 15 (1): 48. doi:10.3390/ph15010048. ISSN 1424-8247.
  4. Chimalakonda A, Burke J, Cheng L, Catlett I, Tagen M, Zhao Q, et al. (October 2021). "Selectivity Profile of the Tyrosine Kinase 2 Inhibitor Deucravacitinib Compared with Janus Kinase 1/2/3 Inhibitors". Dermatology and Therapy. 11 (5): 1763–1776. doi:10.1007/s13555-021-00596-8. PMC 8484413. PMID 34471993.
  5. Mullard A (September 2022). "First de novo deuterated drug poised for approval". Nature Reviews. Drug Discovery. 21 (9): 623–625. doi:10.1038/d41573-022-00139-6. PMID 35974147. S2CID 251623586.
  6. "U.S. Food and Drug Administration Approves Sotyktu™ (deucravacitinib), Oral Treatment for Adults with Moderate-to-Severe Plaque Psoriasis". Business Wire (Press release). 10 September 2022. Archived from the original on 10 September 2022. Retrieved 10 September 2022.

External links

External sites: